STRA6 Expression Serves as a Prognostic Biomarker of Gastric Cancer.
Aged
Biomarkers, Tumor
/ analysis
Cell Line, Tumor
Cohort Studies
Datasets as Topic
Disease-Free Survival
Female
Gastrectomy
Humans
Male
Membrane Proteins
/ analysis
Middle Aged
Oligonucleotide Array Sequence Analysis
Prognosis
RNA-Seq
Risk Factors
Stomach
/ pathology
Stomach Neoplasms
/ mortality
Survival Rate
Gastric cancer
STRA6
biomarker
prognosis
recurrence
Journal
Cancer genomics & proteomics
ISSN: 1790-6245
Titre abrégé: Cancer Genomics Proteomics
Pays: Greece
ID NLM: 101188791
Informations de publication
Date de publication:
Historique:
received:
15
04
2020
revised:
20
05
2020
accepted:
29
05
2020
entrez:
30
8
2020
pubmed:
30
8
2020
medline:
6
5
2021
Statut:
ppublish
Résumé
Despite advances in our understanding on the pathogenesis of gastric cancer (GC), patients face a poor prognosis. To improve clinical outcomes, effective approaches to diagnosis and treatment employing new diagnostic biomarkers are required to achieve early detection and predict recurrence and prognosis. Transcriptome analysis was conducted using surgically resected gastric tissues from four patients with metastatic GC. A total of 228 pairs of primary GC tissues and corresponding normal adjacent tissues were subjected to mRNA expression analysis. To validate our findings, we accessed an integrated microarray dataset and RNA sequencing data of GC cell lines. We identified stimulated by retinoic acid 6 (STRA6) as a differentially overexpressed gene, which encodes a transmembrane protein that mediates the cellular uptake of retinol. To investigate how STRA6 contributes to the malignant phenotype of GC cells, we mined public datasets and found the mRNA encoding retinol binding protein 1 (RBP1), which is associated with retinoid metabolism, was co-expressed with STRA6. Furthermore, STRA6 mRNA levels were significantly higher in GC tissues compared to the corresponding noncancerous adjacent tissues of 228 surgically resected gastric tissue samples. Moreover, patients with high levels of STRA6 mRNA experienced significantly shorter disease-free survival and overall survival. Multivariate analysis revealed that high levels of STRA6 served as a significant risk factor. Patients with high levels of STRA6 mRNA experienced significantly worse clinical outcomes, indicating that STRA6 may serve as a diagnostic and prognostic biomarker of GC.
Sections du résumé
BACKGROUND
BACKGROUND
Despite advances in our understanding on the pathogenesis of gastric cancer (GC), patients face a poor prognosis. To improve clinical outcomes, effective approaches to diagnosis and treatment employing new diagnostic biomarkers are required to achieve early detection and predict recurrence and prognosis.
MATERIALS AND METHODS
METHODS
Transcriptome analysis was conducted using surgically resected gastric tissues from four patients with metastatic GC. A total of 228 pairs of primary GC tissues and corresponding normal adjacent tissues were subjected to mRNA expression analysis. To validate our findings, we accessed an integrated microarray dataset and RNA sequencing data of GC cell lines.
RESULTS
RESULTS
We identified stimulated by retinoic acid 6 (STRA6) as a differentially overexpressed gene, which encodes a transmembrane protein that mediates the cellular uptake of retinol. To investigate how STRA6 contributes to the malignant phenotype of GC cells, we mined public datasets and found the mRNA encoding retinol binding protein 1 (RBP1), which is associated with retinoid metabolism, was co-expressed with STRA6. Furthermore, STRA6 mRNA levels were significantly higher in GC tissues compared to the corresponding noncancerous adjacent tissues of 228 surgically resected gastric tissue samples. Moreover, patients with high levels of STRA6 mRNA experienced significantly shorter disease-free survival and overall survival. Multivariate analysis revealed that high levels of STRA6 served as a significant risk factor.
CONCLUSION
CONCLUSIONS
Patients with high levels of STRA6 mRNA experienced significantly worse clinical outcomes, indicating that STRA6 may serve as a diagnostic and prognostic biomarker of GC.
Identifiants
pubmed: 32859629
pii: 17/5/509
doi: 10.21873/cgp.20207
pmc: PMC7472443
doi:
Substances chimiques
Biomarkers, Tumor
0
Membrane Proteins
0
STRA6 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
509-516Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Gastric Cancer. 2020 Mar;23(2):203-211
pubmed: 31377880
Ann Surg Oncol. 2019 Mar;26(3):836-844
pubmed: 30617870
Oncotarget. 2018 Apr 10;9(27):18775-18785
pubmed: 29721160
Cell Mol Gastroenterol Hepatol. 2017 Jan 14;3(2):211-217
pubmed: 28275688
Int J Cancer. 2020 May 15;146(10):2865-2876
pubmed: 31597194
Expert Rev Anticancer Ther. 2019 Sep;19(9):757-771
pubmed: 31437076
Oncogene. 2018 Sep;37(39):5355-5366
pubmed: 29858600
Gastric Cancer. 2019 Nov;22(6):1143-1152
pubmed: 31055693
Ann Surg. 2018 Mar;267(3):495-503
pubmed: 28026832
World J Gastroenterol. 2015 Sep 14;21(34):9838-52
pubmed: 26379391
Gastric Cancer. 2017 Jan;20(1):1-19
pubmed: 27342689
Oncol Rep. 2018 Dec;40(6):3772-3780
pubmed: 30272363
Cancer Res. 2001 May 15;61(10):4197-205
pubmed: 11358845
Curr Top Microbiol Immunol. 2017;400:277-304
pubmed: 28124158
Stem Cell Reports. 2017 Aug 8;9(2):438-450
pubmed: 28689994
Cell Death Differ. 2013 Jul;20(7):910-9
pubmed: 23449393
Surgery. 2015 Dec;158(6):1573-80
pubmed: 26120068
Subcell Biochem. 2016;81:77-93
pubmed: 27830501
Anticancer Res. 2020 Mar;40(3):1691-1695
pubmed: 32132076
Gastric Cancer. 2019 Nov;22(6):1215-1225
pubmed: 30955110
Cancer Res. 2014 Nov 1;74(21):6341-51
pubmed: 25237067
Br J Surg. 2018 Sep;105(10):1349-1358
pubmed: 29741294